V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck by Zuleyha Akgun et al.
Akgun et al. Radiation Oncology 2014, 9:104
http://www.ro-journal.com/content/9/1/104RESEARCH Open AccessV30 as a predictor for radiation-induced
hypothyroidism: a dosimetric analysis in patients
who received radiotherapy to the neck
Zuleyha Akgun1*, Beste M Atasoy2, Zeynep Ozen3, Dilek Yavuz4, Bahadir Gulluoglu5, Meric Sengoz6
and Ufuk Abacioglu3Abstract
Introduction: The purpose of this study is to evaluate the possible predictors of thyroid disorders after neck
radiotherapy, with a focus on radiation dose-volume factors.
Methods: Thyroid function was measured in 100 patients who had received radiotherapy to the neck, including
the thyroid. All radiation-induced thyroid dysfunctions were determined with an endpoint of abnormal thyroid
stimulating hormone (TSH), free triiodothyronine (fT3) and thyroxine (fT4) and thyroid peroxidase antibodies and
(TPA). The total volume of the thyroid, mean radiation dose to the thyroid (Dmean) and thyroid volume percentage
that received radiation doses of 10–50 Gy (V10-V50) were calculated in all patients. The evaluated risk factors for
thyroid dysfunction included dose-volume parameters, sex, age, previous surgery, chemotherapy and comorbidity.
Results: There were 52 patients with hypothyroidism and V30 (p = 0.03), thyroid volume (p = 0.01) and Dmean
(p = 0.03) appeared to be correlated with hypothyroidism in univariate analysis. However, there was not association
found in multivariate analysis for these factors.
Conclusions: Thyroid disorders after radiation therapy to the neck still represent a clinically underestimated
problem. V30 may be a useful tool for evaluating the risk of hypothyroidism when determining an individual
patient’s treatment.
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The thyroid gland is one the most radiosensitive normal
tissues in the human body. It is frequently affected by
radiotherapy in head and neck patients, and thyroid dys-
functions are commonly seen following irradiation [1,2].
The incidence of radiation-induced hypothyroidism has
been described mostly within the range of 20–30% and
the reports are currently increasing in literature [1-25].
Nonetheless, it still remains an underestimated problem
in routine clinical practice [3-5]. Some dosimetric stu-
dies exploring radiation-induced thyroid dysfunction
have suggested that a thyroid dose of ≥30 Gy is as-
sociated with higher risk for hypothyroidism [1,4,6,7].* Correspondence: zuleyhaakgun@gmail.com
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unless otherwise stated.However, Kim et al. [8] found that the percentage of
thyroid volume absorbing >45 Gy was observed to be
the optimal variable for predicting the development of
hypothyroidism, and they suggested a V45 of 50% as a
possible dose-volumetric threshold for radiation-induced
hypothyroidism.
In this study, we aimed to evaluate the incidence of
thyroid dysfunction following radiotherapy and to ex-
plore any potential correlation between thyroid dysfunc-
tion and radiation doses in our patients.Methods
This study was approved by the Ethical Committee of
Marmara University School of Medicine. Between May
2005 and March 2010, 106 patients who had histologi-
cally proven non-thyroid malignancies located in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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were recruited for the analysis. The patients who had
existing thyroid dysfunction (n = 6) before radiotherapy
were excluded from the analysis. There were 30 patients
who had surgery to primary tumor and/or neck before
radiotherapy. All patients were irradiated at the primary
site and the neck and were regularly followed after
radiotherapy. The patients and treatment characteristics
are summarized in Table 1.Radiotherapy
All patients underwent our center’s routine procedure for
head and neck tumor patients. The patients first under-
went a simulation using immobilization with a thermo-
plastic mask to ensure a reproducible set-up. The patients
then underwent a treatment-planning computed tomo-
graphy (CT) scan with images obtained at 3- to 5-mm
slice intervals. The data were transferred to the planning
system and 3-D treatment planning using Eclipse (Varian
Medical Systems, Palo Alto, CA, USA) was performed
for all the patients. Either two opposite equally weighted
lateral fields plus one anterior field or anterior-posterior
fields or five fields, were used. Treatment was performed
with photons (6 MV or 18 MV) and/or electrons (6 MeV,
9 MeV to 12 MeV) using a linear accelerator (Saturne 42,
800 series, General Electric, Buc, France). A total median
dose of 60 Gy (range, 36–70 Gy) in 20 to 35 daily fractions
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Taxane 75 mg/m2/21 d and cisplatin 75 mg/m2/21 d
Concomitant 31
Cisplatin 75 mg/m2/21 d
Previous surgery to primary tumor side and/or neck 30
Comorbidity (diabetes and/or hypertension) 17Dosimetric analysis
Treatment plans from all patients were included in this
study and the thyroid gland was contoured on each indi-
vidual CT-slice by the same Radiation Oncologist (ZA).
The minimum (Dmin), the maximum (Dmax) and the
mean (Dmean) doses the thyroid gland received and the
percentage of thyroid volume receiving 10 Gy (V10), 20
Gy (V20), 30 Gy (V30), 40 Gy (V40) and 50 Gy (V50)
were calculated using dose volume histograms.
Thyroid function assessments
The patients were followed for thyroid functions after the
completion of radiotherapy with periodic thyroid stimu-
lant hormone (TSH), free thyroxin (fT4), free triiodothy-
ronine (fT3) and thyroid peroxidase antibody (TPA) tests.
The first test was obtained at 3 to 6 months after radio-
therapy, with the next test at a six months interval there-
after. All tests were measured in the same laboratory
using electrochemiluminescence methods (Roche Elecsys
2010 immunoassay analyzer, Roche Diagnostics GmbH,
Mannheim, Germany). According to recommendations
from the American Thyroid Association, hypothyroidism
was defined as a TSH value greater than the upper limit of
the normal range. The upper cut off range for TSH that
was used was 4 mIU/L for individuals under 60 years old,
6 mIU/L for those in the 7th decade and 7 for those in the
8th decade [9].
Statistical analysis
Statistical analyses were performed using NCSS 2007 &
PASS 2008 Statistical Software (Utah, USA). For statis-
tical analysis, we evaluated the following variables: thy-
roid absorbed dose, thyroid volume, previous surgery to
the primary tumor or to neck, chemotherapy, comor-
bidity, age, and sex. The relationship between any clin-
ical or treatment parameter and the incidence of thyroid
function disorders were analyzed using the appropriate
chi-square test or Fisher’s exact test for categorical vari-
ables and the nonparametric Mann–Whitney U test for
continuous variables. The median and range were used
to describe all continuous variables. The chi-square test
was used to assess the data for correlations among the
dose-volume parameters. Continuous variables were di-
chotomized at median (range) values. A multivariate was
used (logistic regression analysis with backward variable
selection) and β value were calculated for the variables
that found significant in univariate analysis. P < 0.05
were regarded as significant.
Results
The median follow-up was 47 months (range, 11 to 80
months). There were 52 patients in whom previous thy-
roid function tests had been reached. All thyroid func-
tion test results were in normal range and none of the
Table 3 Clinical and dosemiteric factors in patients with
and without hypothyroidism
Normal Hypothyroidism P
(n = 48) (n = 52)
Median Age (year) 53 48 0.23
Comorbidity 9 8 0.30
Surgery 16 14 0.26





Thyroid volume 31.59 (5.7–99) 14.25 (0.6–69.6) 0.01
Dmin (≥40.1 Gy) 48.1 (0–61.0) 52.1 (0.6–59.7) 0.42
Dmax (≥57.6 Gy) 50 (19.9–75.3) 47.9 (19.4–71.0) 0.49
Dmean (≥47.3 Gy) 44.2 (5.7–67.3) 56.2 (3.8–66.5) 0.03
V10 (≥100%) 75.0 (13–100) 89.1 (9–100) 0.06
V20 (≥100%) 67.5 (7–100) 82.6 (0–100) 0.06
V30 (≥100%) 59.6 (0–100) 78.3 (0–100) 0.03
V40 (≥94%) 45.9 (0–100) 53.6 (0–100) 0.36
V50 (≥44%) 54.8 (0–100) 45.2 (0–100) 0.06
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radiotherapy. During the follow-up, 52 patients
developed clinical hypothyroidism and they all were
treated with levothyroxine. There were 12 patients who
developed thyroiditis, as determined by thyroid ultra-
sound findings. There were no cases of hypothyroidism
(in which the low level of TSH is associated with low
levels of fT3 and/or fT4) or hyperthyroidism (in which
the high level of TSH is associated with high levels of
fT3 and/or fT4) related to pituitary gland dysfunction.
The patients’ distribution in numbers according to the
time that hypothyroidism was detected is shown in
Table 2. In summary, the incidence of first diagnosis of
hypothyroidism was highest in the first year, especially
in the second 6th month period.
The univariate analysis for clinical and dosimetric pa-
rameters are shown in Table 3. There were no correlations
observed between the incidence of hypothyroidism and
the patients’ comorbidity, previous surgery, chemotherapy,
age and gender. Additionally, there were no significant
relationships observed between Dmax or Dmin and hy-
pothyroidism. However, Dmean (p = 0.03), the thyroid vo-
lume (31.59 cc vs. 14.25 cc; p = 0.01) and the analysis of
irradiated thyroid volume threshold showed that having
whole of thyroid volume irradiated to 30 Gy was
a statistically significant predictor for hypothyroidism
(p = 0.03). Meanwhile, V10, V20, V40 or V50 were not
found to be associated with higher risks of thyroid dis-
order. In multivariate analysis there was no correlation
found for significant parameters of Vmean (p = 0.627,
β = −0.102), thyroid volume (p = 0.06, β = −0.188) or V30
(p = 0.07, β = 0.181).
Discussions
The thresholds for direct thyroid radiation damage are
not clear. Investigators have previously reported that theTable 2 The number of patients developed
hypothyroidism according to month intervals












67-72 1incidence of hypothyroidism in various series of patients
treated for head and neck cancer varies in a wide range
[1-25]. However, most reports state the incidence to be
between 20% and 53% and the incidence of 52% found in
our study is consistent with these findings. Several dosi-
metric studies about radiotherapy related thyroid dysfunc-
tion and dose volume distribution have been performed in
patients receiving irradiation to the thyroid gland
[5,7,8,10,11]. Yoden et al. [14] reported that the correl-
ation between the percentage of the volume receiving 10
Gy (V10), 20 Gy (V20) and 30 Gy (V30) is a possible pre-
dictor of hypothyroidism. Additionally, Bhandare et al. [5]
reported a possible dose-volume effect on the increase in
the incidence of hypothyroidism, with an increased inci-
dence when 50% of the thyroid volume received greater
radiation doses. Our data showed that V30 was a statisti-
cally significant predictor of the development of hypothy-
roidism (p = 0.03). In our study, the thyoid gland was an
organ at risk in the treatment field instead of being a tar-
get tissue received high doses. There were fewer patients
that the gland received high doses like primary tumor
(≥40 Gy) and this may be the reason the insignificant cor-
relation for V40 and V50.
Jerezeck et al. [4] showed that smaller thyroid volume
was associated with a higher incidence of thyroid toxi-
city, and Diaz et al. [19] also reported similar findings.
Cella et al. [20] developed a multivariate NTCP model
for radiation-induced hypothyroidism including V30 and
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correlation between thyroid volume and hypothyroidism
(p = 0.01). This correlation may be explained by previous
surgical procedure. The incidence of hypothyroidism in-
duced by radiotherapy depends on the type of surgical
procedure and is high in patients in whom hemithyroi-
dectomy was performed as a part of surgery. Biel et al.
[23] showed that the incidence of hypothyroidism in
groups of only surgery, radiotherapy and radiotherapy
after surgery patients was 47%, 23% and 70%, respectively.
These data have been validated by other authors [6,14,25].
The effect of age on hypothyroidism after radiotherapy
is not clear. Hancock et al. [1] showed that there is a re-
lationship between hypothyroidism and age. Previous
studies by Posner [21] and Hancock [1] showed that
female patients had an increased risk for hypothyroidism
after radiotherapy. Vrabec et al. [22] observed that
female patients had smaller thyroid reserve. However,
there are some studies that have shown that there is no
correlation between sex and hypothyroidism [18]. We
did not find any correlation between sex and thyroid
function disorder after radiotherapy in our study. We
did not find any correlation between chemotherapy and
comorbidity, either.
Radiation-induced hypothyroidism develops after a
median interval of 1–1.8 years [21-23]. In our study,
hypothyroidism developed 7–24 months after the com-
pletion of treatment (Table 2). Therefore, it may be
recommended to perform a regular TSH level test from
6th months follow-up after radiotherapy.
In conclusion, the clinical and dosimetric predictors of
radiation induced thyroid disorders are not typically dis-
tinguished. We found a significant association between
the development of hypothyroidism and the V30. There-
fore, the V30 may be useful in comparing competing
treatment plans to evaluate the risk of hypothyroidism
when designing individual patients’ treatment.
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